New antibody cocktail takes aim at tough childhood cancers

NCT ID NCT04751383

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This early-phase trial tested two lab-made antibodies, magrolimab and dinutuximab, together in 12 children and young adults whose neuroblastoma or osteosarcoma had returned or stopped responding to treatment. The main goal was to find a safe dose and watch for side effects. Researchers also checked whether the combination could shrink tumors or keep them stable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magrolimab and dinutuximab (monoclonal antibodies)
What this could lead to: If it works, this could point toward a new combination treatment for children with hard-to-treat neuroblastoma or osteosarcoma.
What could go wrong: This is a very early, small phase 1 trial with only 12 participants, focused on safety and dosing. It is not designed to prove effectiveness, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

localized osteosarcoma neuroblastoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NEUROBLASTOMA RECURRENT NEUROBLASTOMA RECURRENT OSTEOSARCOMA REFRACTORY NEUROBLASTOMA RESECTABLE OSTEOSARCOMA

Contacts and locations

Locations

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
British Columbia Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada
Lucile Packard Children's Hospital Stanford University

Palo Alto, California, 94304, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.